Ekso Bionics (NASDAQ:EKSO) Receives Buy Rating from HC Wainwright

Ekso Bionics (NASDAQ:EKSO)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $9.00 price objective on the stock.

Separately, StockNews.com started coverage on Ekso Bionics in a research report on Monday. They set a “hold” rating on the stock.

Ekso Bionics Stock Down 8.1 %

Shares of NASDAQ EKSO opened at $0.48 on Tuesday. The firm has a fifty day simple moving average of $0.61 and a two-hundred day simple moving average of $0.83. Ekso Bionics has a 12 month low of $0.45 and a 12 month high of $2.16. The company has a current ratio of 2.81, a quick ratio of 2.14 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $10.61 million, a PE ratio of -0.74 and a beta of 1.46.

Ekso Bionics (NASDAQ:EKSO) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.07). The company had revenue of $5.09 million during the quarter, compared to the consensus estimate of $5.05 million. Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. Equities analysts expect that Ekso Bionics will post -0.48 earnings per share for the current year.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.